速递｜减重新药出海中东！派格生物新药授权中东及非洲的独家许可

Core Viewpoint - The article discusses the collaboration between Paig Bio and PDC FZ-LLC for the exclusive licensing of the innovative drug Visepagendide (PB-119), a GLP-1 receptor agonist aimed at treating type 2 diabetes and weight management in the Middle East and Africa [2][3][4]. Group 1: Product Overview - Visepagendide (PB-119) is a weekly administered GLP-1 receptor agonist developed by Paig Bio, showing good safety, tolerability, and significant effects on blood sugar reduction and weight loss in clinical studies [3]. - The product's innovative molecular structure and long-acting mechanism provide a more convenient and stable treatment option, positioning it as a representative of the next generation of GLP-1 therapies [3]. Group 2: Market Potential - The Middle East and Africa are rapidly growing markets for diabetes and obesity treatment drugs, with a high prevalence of related diseases indicating a strong potential demand for innovative therapies like PB-119 [3]. - The collaboration with PDC, a leading pharmaceutical research organization in the region, is expected to enhance the market entry and commercialization of PB-119 [3][4]. Group 3: Strategic Partnership - PDC will have exclusive rights to develop, register, produce, distribute, market, and commercialize PB-119 in the Middle East and Africa, including comprehensive technology transfer and local production [2][3]. - The partnership reflects Paig Bio's strong R&D capabilities and the promising clinical performance of PB-119, further solidifying its position in the metabolic disease sector [4].